دورية أكاديمية
Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer : report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022
| العنوان: | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer : report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 |
|---|---|
| المؤلفون: | Gillessen, Silke, Bossi, Alberto, Davis, Ian D., de Bono, Johann, Fizazi, Karim, James, Nicholas D., Mottet, Nicolas, Shore, Neal, Small, Eric, Smith, Matthew, Sweeney, Christopher J., Tombal, Bertrand, Antonarakis, Emmanuel S., Aparicio, Ana M., Armstrong, Andrew J., Attard, Gerhardt, Beer, Tomasz M., Beltran, Himisha, Bjartell, Anders, Blanchard, Pierre, Briganti, Alberto, Bristow, Rob G., Bulbul, Muhammad, Caffo, Orazio, Castellano, Daniel, Castro, Elena, Cheng, Heather H., Chi, Kim N., Chowdhury, Simon, Clarke, Caroline S., Clarke, Noel, Daugaard, Gedske, De Santis, Maria, Duran, Ignacio, Eeles, Ross, Efstathiou, Eleni, Efstathiou, Jason, Ekeke, Onyeanunam Ngozi, Evans, Christopher P., Fanti, Stefano, Feng, Felix Y., Fonteyne, Valerie, Fossati, Nicola, Frydenberg, Mark, George, Dan, Gleave, Martin, Gravis, Gwenaelle, Halabi, Susan, Heinrich, Daniel, Herrmann, Ken, Higano, Celestia, Hofman, Michael S., Horvath, Lisa G., Hussain, Maha, Jereczek-Fossa, Barbara A., Jones, Rob, Kanesvaran, Ravindran, Kellokumpu-Lehtinen, Pirkko-Liisa, Khauli, Raja B., Klotz, Laurence, Kramer, Gero, Leibowitz, Raja, Logothetis, Christopher, Mahal, Brandon, Maluf, Fernando, Mateo, Joaquin, Matheson, David, Mehra, Niven, Merseburger, Axel, Morgans, Alicia K., Morris, Michael J., Mrabti, Hind, Mukherji, Deborah, Murphy, Declan G., Murthy, Vedang, Nguyen, Paul L., Oh, William K., Ost, Piet, O'Sullivan, Joe M., Padhani, Anwar R., Pezaro, Carmel J., Poon, Darren M. C., Pritchard, Colin C., Rabah, Danny M., Rathkopf, Dana, Reiter, Robert E., Rubin, Mark A., Ryan, Charles J., Saad, Fred, Sade, Juan Pablo, Sartor, Oliver, Scher, Howard I., Sharifi, Nima, Skoneczna, Iwona, Soule, Howard, Spratt, Daniel E., Srinivas, Sandy, Sternberg, Cora N., Steuber, Thomas, Suzuki, Hiroyoshi, Sydes, Matthew R., Taplin, Mary-Ellen, Tilki, Derya, Turkeri, Levent, Turco, Fabio, Uemura, Hiroji, Uemura, Hirotsugu, Urun, Yuksel, Vale, Claire L., van Oort, Inge, Vapiwala, Neha, Walz, Jochen, Yamoah, Kosj, Ye, Dingwei, Yu, Evan Y., Zapatero, Almudena, Zilli, Thomas, Omlin, Aurelius |
| المصدر: | EUROPEAN JOURNAL OF CANCER ; ISSN: 0959-8049 ; ISSN: 1879-0852 |
| سنة النشر: | 2023 |
| المجموعة: | Ghent University Academic Bibliography |
| مصطلحات موضوعية: | Medicine and Health Sciences, PSMA PET-imaging, Next-generation imaging, Androgen receptor pathway inhibitors (ARPI), Chemotherapy, Systemic therapy, Hormonal treatment, Metastatic castration-resistant prostate cancer (mCRPC) and oligometastatic and oligoprogressive prostate cancer, Non metastatic castration-resistant prostate cancer (nmCRPC), Metastatic hormone-sensitive prostate cancer (mHSPC) |
| الوصف: | Background: Innovations in imaging and molecular characterisation together with novel treatment options have improved outcomes in advanced prostate cancer. However, we still lack high-level evidence in many areas relevant to making management decisions in daily clinical practise. The 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) addressed some questions in these areas to supplement guidelines that mostly are based on level 1 evidence. Objective: To present the voting results of the APCCC 2022.Design, setting, and participants: The experts voted on controversial questions where high-level evidence is mostly lacking: locally advanced prostate cancer; biochemical recurrence after local treatment; metastatic hormone-sensitive, non-metastatic, and metastatic castration-resistant prostate cancer; oligometastatic prostate cancer; and managing side effects of hor-monal therapy. A panel of 105 international prostate cancer experts voted on the consensus questions.Outcome measurements and statistical analysis: The panel voted on 198 pre-defined questions, which were developed by 117 voting and non-voting panel members prior to the conference following a modified Delphi process. A total of 116 questions on metastatic and/or castration-resistant prostate cancer are discussed in this manuscript. In 2022, the voting was done by a web-based survey because of COVID-19 restrictions.Results and limitations: The voting reflects the expert opinion of these panellists and did not incorporate a standard literature review or formal meta-analysis. The answer options for the consensus questions received varying degrees of support from panellists, as reflected in this article and the detailed voting results are reported in the supplementary material. We report here on topics in metastatic, hormone-sensitive prostate cancer (mHSPC), non-metastatic, castration-resistant prostate cancer (nmCRPC), metastatic castration-resistant prostate cancer (mCRPC), and oligometastatic and oligoprogressive prostate cancer.Conclusions: ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| العلاقة: | https://biblio.ugent.be/publication/01HY0E617P5RF4V85SZ8HCRGRFTest; http://hdl.handle.net/1854/LU-01HY0E617P5RF4V85SZ8HCRGRFTest; http://doi.org/10.1016/j.ejca.2023.02.018Test; https://biblio.ugent.be/publication/01HY0E617P5RF4V85SZ8HCRGRF/file/01HY0YFXWHN8GM2X46ASH8JGMTTest |
| DOI: | 10.1016/j.ejca.2023.02.018 |
| الإتاحة: | https://doi.org/10.1016/j.ejca.2023.02.018Test https://biblio.ugent.be/publication/01HY0E617P5RF4V85SZ8HCRGRFTest http://hdl.handle.net/1854/LU-01HY0E617P5RF4V85SZ8HCRGRFTest https://biblio.ugent.be/publication/01HY0E617P5RF4V85SZ8HCRGRF/file/01HY0YFXWHN8GM2X46ASH8JGMTTest |
| حقوق: | Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License (CC BY-NC-ND 4.0) ; info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.D4C3D1A1 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.ejca.2023.02.018 |
|---|